|
The lot history records have been reviewed with special attention to the manufacturing and inspection of this product and the product was found to have met all specifications prior to shipment.As part of all complaint investigations, an attempt was made to evaluate the subject device as well as the device usage.In this case, no sample or image was provided for evaluation.Therefore, the reported event could not be reproduced.Potential contributing factors to the reported event have been evaluated.Previous investigations of similar complaints have been reviewed.A difficult vessel anatomy or insufficient flushing of the device may be contributing factors to the reported event.In this case, the anatomy of the tracking vessel and the target lesion was not tortuous or calcified.The system was flushed prior to use and there were no difficulties in advancing the delivery system to the target site.The lesion had been pre-dilated.However, the reported application represents an off-label use of the device and may be another contributing factor to the reported event.On the basis of the information available and as no sample was returned for evaluation, a definite root cause for the reported event could not be determined.The ifu states: "visually inspect the bard e-luminexx vascular stent to verify that the device has not been damaged due to shipping or improper storage.Do not use damaged equipment." and "should unusual resistance be felt at any time during the procedure, the entire system(introducer sheath or guiding catheter and stent delivery system) should be removed as a single unit." in addition, the ifu indicates that the device is intended for use in the treatment of iliac occlusive disease or in the treatment of biliary strictures.The information provided by bard represents all of the known information at this time.Despite good faith efforts to obtain additional information, the complainant was unable to provide any patient or further procedural details.
|